Work experience
2013.01-present    Professor, Department of medical oncology, Cancer center of Sun Yat-sen University, China

2010.08 -2010.12    Clinical observer, Breast Cancer Medicine service

Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA

2007.01-2012.12   Associate professor,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

2004.07- 2006.12   Lecturer & Attending Physician,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

1998.07 -2001.08    Lecturer & attending physician,

Affiliated hospital of Xuzhou Medical College, China

1992.07 -1995.08    Resident physician,

Affiliated hospital of Xuzhou Medical College, China

1. Familiar with medical oncology and phase I, II, III Clinical trials

2. Cell culture and purification of protein. 

3. In vitro and in vivo study of anti-cancer drugs

4. Molecular biological techniques

2001-2004 Ph.D. in Medical Oncology, Sun Yat-sen University, China

1995-1998 M.S. in Medical Oncology, Henan Medical University, China 

1987-1992 M.D. in Clinical Medicine, Xuzhou Medical College, China

1.       Fu L, Shi K, Wang J, ChenW, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpressioncontributes to tumor growth and a poor prognosis of human lung adenocarcinomathrough modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89  (corresponding author)

2.       Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, FuL, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerasereverse transcriptase and predicts poor prognosis in human lungadenocarcinomas. Mol Oncol. 2014May;8(3):704-716  (correspondingauthor)

3.       ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua,LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene inPostmenopausal Operable Patients with Luminal Subtype of Breast Cancer asCompared with Tamoxifen:A Retrospective Study in China. Chin J Bases ClinGeneral Surg,  2014,21( 5):555-561(correspondingauthor)

4.       Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J BasesClin General Surg, 2014, 21( 5):544-548(corresponding author)　

5.       Qin T, Yuan ZY, PengRJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, WangSS .Efficacy andtolerability of toremifene and tamoxifen therapy in premenopausal patients withoperable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9  (correspondingauthor)

6.        Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,LiuDG, Bai B, Wang SS .HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that ofHER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47   (corresponding author)

7.       QIN Tao, YUAN Zhong-yu, PENGRou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with LuminalSubtype Early Breast Cancer： A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY（MEDICAL SCIENCES）,2013,34(3):402-406(corresponding author)

8.       Fu ly, Chen WB, Guo W, WangJS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS,Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF andCytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13  (correspondingauthor)

9.       Gu WG, Huang Y, YuanZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin aloneor in combination for treatment of a nasopharyngeal carcinoma cell line andXenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (correspondingauthor)

10.   Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li,Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavageand polyadenylation specific factor 4 in lung adenocarcinoma and its criticalrole for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)

11.    Wang S, Shi Y,Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. ClassicalCMF regimen as adjuvant chemotherapy for triple-negative breast cancer may bemore effective compared with anthracycline or taxane-based regimens. Med Oncol.2012,29:547-553 (first author)

12.    He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgenreceptor expression in operable triple negative breast cancer: A retrospectiveanalysis based on a tissue microarray. Med Oncol 2012,29:406-410

13.     Liu D, He J,Yuan Z, Wang S, Peng R, Shi Y, TengX, Qin T. EGFR expression correlates with decreased disease-free survival intriple negative breast cancer: A retrospective analysis based on a tissuemicroarray. Med Oncol. 2012,29:401-405

14.   Shi YX, Tan YT,Yuan ZY, Wang SS, Peng RJ, An X, CaoY, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survivalbetween the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breast cancer.Med Oncol 2012,29:39-47

15.   Shi YX, Xia Q,Peng RJ, Yuan ZY, Wang SS, An X, CaoY, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714

16.    Wang x, Wang SS,Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG,  Yuan ZY. Interaction of coping styles andpsychological stress on anxious and depressive symptoms in Chinese breastcancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. （IF：1.24）

17.   PengR, Wang S, Shi Y, Liu D, Teng X, QinT, Zeng Y, Yuan Z. Patients 35 years old oryounger with operable breast cancer are more at risk for relapse and survival:A retrospective matched case-control study. Breast. 2011; 20: 568-573.（IF：2.089）

18.    Liu DG, WangSS, Peng RJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY. Interaction of Social Support andPsychological Stress on Anxiety and Depressive Symptoms in Breast CancerPatients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. （IF：1.24）

19.   Bing Bai, Shusen Wang et al. Clinical Featuresand Survival Analysis of Different  Subtypesof   Patients with Breast Cancer BrainMetastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author)

20.   Qin jianyong Wang shusen,YIN CHUANZHONG The legaland ethic issues in operating medical information service website. JOURNAL OFMEDICAL INFORMATICS,2010,31(8):52-55

21.   Yuan zhongyu,Shusen Wang, et al.  Clinical Characteristics and Prognosis ofTriple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal ofCancer, 2008, 27(6)..

22.   Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis ofdifferent subtypes of breast cancer Chinese Journal of Oncology.  2008 ,30(6):456-61

23.   Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma.Chinesr journal of cancer 2008,27(11):1197-1203

24.   CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al.Primary Breast Lymphoma —A Report of 27 Cases withLiterature Review Chinese Journalof Cancer, 2007, 26( 1) : 84- 89

25.   Xiao Jian, Wang Shusen, Huang Yan et al.  Expression of CD117 and PDGFRa in ExtranodularNK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology2,007 34(11):615-617

26.   QIU Miao-Zhen, XUFei, WANG Shu-Sen et al.Responses of 109 Adult Soft Tis sue Sarcoma Patientsto Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349

27.    Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expressionin Nasopharyngeal Carcinoma，Chinese Journal of Oncology.2006,28(1).

28.    Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1Expression in Nasopharyngeal Carcinoma，Chinese Journalof Clinical Oncology，2005,32,(6)

29.    Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth FactorReceptor-Selective Tyrosine Kinase Inhibitor Gefitinib on NasopharyngealCarcinoma. Chinese Journal of Cancer, 2004,23(11s).

30.   Yanqun Xiang, Shusen Wang, et al Prognostic Value ofSurviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).

31.    Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. ChineseJournal of Medicine.2004, 4(1): 24-29.

32.    Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. ChineseJournal of Cancer Palliative Medicine. 2003,2(4): 239-242.

33.    Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According toGood Clinical Practice. National Medical Journal of China.2003,83(3):179-180.

34.    Shusen Wang , Ruilin Wang, et al. Study on the Purification of AngiogenesisInhibitor from Shark Cartilage and its Biological Characteristics. HenanJournal of Oncololgy.1999, 12(3): 179-181.

35.    Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 EndothelialCells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998,18 (3): 176-178.

36.   Jinchuan Zhang, Shusen Wang, et al. Detecting TumorSpecific Growth Factor in Patients with Chemotherapy. Academiae MedicinaeXuzhou.2001, 21(2): 116-117.

37.   Desheng liu, Shusen Wang et al. How to Improve theEffect and Safety of Three-Step Method of Analgesia. Chinese Journal ofClinical Oncology and Recovery.1999, 6 (5): 77-79. 

Updated by International Office, Sun Yat-sen University Cancer Center